Aquestive Therapeutics (AQST) Debt to Equity (2017 - 2025)
Historic Debt to Equity for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$8.83.
- Aquestive Therapeutics' Debt to Equity fell 118169.19% to -$8.83 in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.83, marking a year-over-year decrease of 118169.19%. This contributed to the annual value of -$0.54 for FY2024, which is 10914.24% down from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' Debt to Equity is -$8.83, which was down 118169.19% from -$0.48 recorded in Q2 2025.
- Aquestive Therapeutics' Debt to Equity's 5-year high stood at -$0.26 during Q4 2023, with a 5-year trough of -$8.83 in Q3 2025.
- Its 5-year average for Debt to Equity is -$1.0, with a median of -$0.56 in 2022.
- Per our database at Business Quant, Aquestive Therapeutics' Debt to Equity soared by 7488.09% in 2021 and then tumbled by 118169.19% in 2025.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Debt to Equity stood at -$0.65 in 2021, then soared by 32.57% to -$0.44 in 2022, then soared by 41.23% to -$0.26 in 2023, then tumbled by 109.14% to -$0.54 in 2024, then plummeted by 1532.39% to -$8.83 in 2025.
- Its Debt to Equity stands at -$8.83 for Q3 2025, versus -$0.48 for Q2 2025 and -$0.55 for Q1 2025.